Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Client Area Book a 7-day Readout
ContraFect Corp logo — ...focused on discovering & developing differentiated biolog...

ContraFect Corp

...focused on discovering & developing differentiated biologic therapies for life-threatening, drug-resistant infections

Founded 2008 United States Yonkers, United States 10 employees Post-IPO Equity Total: $249.07M Biotechnology, Health Care

General Information

Company Name ContraFect Corp
Founded Year 2008
Location United States Yonkers, United States
Founders / Decision Makers
Team member
Employees 10
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with ContraFect Corp. To contact ContraFect Corp, visit contrafect.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ContraFect Corp compare?

A PDF of ContraFect Corp and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ContraFect Corp soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ContraFect Corp

ContraFect Corp is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infections. The company is addressing the pressing issue of antimicrobial-resistant infections, which account for an estimated 700,000 deaths worldwide annually. Through their platform of direct lytic agents (DLAs), including lysins and amurin peptides, ContraFect aims to combat these infections. Their lead lysin candidate, exebacase, has completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia and has been granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections. Furthermore, ContraFect is currently studying exebacase in a pivotal Phase 3 clinical study. ContraFect's approach involves leveraging the unique properties of lysins and amurin peptides, which have demonstrated the ability to target antibiotic-resistant organisms such as MRSA and P. aeruginosa, known to cause serious infections such as bacteremia, pneumonia, and osteomyelitis. The company's efforts are particularly significant in the context of the biotechnology and health care industries. In December 2022, ContraFect Corp received a $7.00M investment in Post-IPO Equity. The company's headquarters is in the United States. Overall, ContraFect Corp is poised to make a significant impact in addressing the global challenge of antibiotic-resistant infections through its innovative biologic therapies.

Business keywords: biologic therapies, drug-resistant infections, direct lytic agents, lysins, amurin peptides, antimicrobial-resistant infections, antibiotic-resistant infections, Phase 2 clinical trial, Phase 3 clinical study, Breakthrough Therapy designation, monoclonal antibodies, multi-drug resistant infections, biotechnology company, Yonkers, New York

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $7.00M -
13 Dec 2022
Post IPO Equity $57.50M -
17 Mar 2021
Grant $18.90M 1
CARB-X
CARB-X
20 Jul 2020
Post IPO Equity $52.50M -
21 May 2020
Post IPO Equity $10.00M -
17 Dec 2019
Grant $7.20M 1
Congressionally Directed Medical Research Programs
Congressionally Directed Medical Research Programs
06 Jun 2019
Grant $2.30M 1
CARB-X
CARB-X
17 Jan 2019
Post IPO Equity $10.00M -
27 Jul 2018
Grant $2.10M 1
CARB-X
CARB-X
30 Mar 2017
Grant $2.10M 1
U.S. Department of Defense
17 Nov 2016

View All 14 Funding Rounds

ContraFect Corp Alternatives & Competitors

View All Alternatives
ContraFect Corp vs
F2G
F2G United Kingdom

The rare fungal disease company

106 employees
Biotechnology, Health Care
Compare ContraFect Corp vs F2G
ContraFect Corp vs
Cardeas Pharma
Cardeas Pharma

Cardeas Pharma is advancing a unique antibiotic formulation combining two drugs with synergistic eff...

Series B
Biotechnology, Health Care
ContraFect Corp vs
Sealife PHARMA® GMBH
Sealife PHARMA® GMBH

Pioneering breakthroughs in marine biochemistry to combat drug-resistant infections and advance the...

Seed
Biotechnology, Health Care
View all alternatives

FAQ About ContraFect Corp

...focused on discovering & developing differentiated biologic therapies for life-threatening, drug-resistant infections
ContraFect Corp was founded in 2008.
ContraFect Corp is headquartered in Yonkers, United States.
ContraFect Corp operates in Biotechnology and Health Care. Its work centres on biologic therapies, drug-resistant infections, direct lytic agents and lysins.
ContraFect Corp has approximately 10 employees.
ContraFect Corp has completed 14 funding rounds, raising a total of $249.07M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to ContraFect Corp include F2G, Cardeas Pharma, Sealife PHARMA® GMBH, Adaptive Phage Therapeutics, Biocidium Biopharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ContraFect Corp and F2G are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ContraFect Corp, https://bouncewatch.com/company/contrafect-corp, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout